Kornimate/medical-research-clean huggingface dataset:
alkalinization by urologists & nephrologists

Conditions: Metabolic Acidosis; Nephrolithiasis; Extracellular Alteration; Blood Pressure; Body Weight

Summary: metabolic acidosis recovers a wide range of diseases in which an oral alkalinization could be useful. this therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure. no prospective data has been published in clinical routine. here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. the principal criterion of evaluation will be the variation in the extracellular compartment.

metabolic acidosis recovers a wide range of diseases - chronic kidney diseases, nephrolithiasis, or others - in which an oral alkalinization could be useful. oral alkalinization could be performed or by bicarbonate contained in alkaline-based waters or drug therapies or by citrate. this therapeutic intervention has been said to increase extracellular volume leading to rising blood pressure, especially due to the amount of daily sodium load. no prospective data has been published in clinical routine, studying its effects on extracellular volume nor the blood pressure control. here, investigators propose to follow patients in which an oral alkalinization is indicated: blood pressure, body weight, and a clinical evaluation of the extracellular compartment will be performed at the beginning and during the follow-up of participants. initial recorded data will be: age, gender, prescription (indication, kind of alkali therapy, volume and duration), body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, comorbidities, drug therapy, blood and urine composition. the recorded follow-up will be: the adherence to treatment, body weight, body length, a clinical appreciation of the extracellular compartment, blood pressure, adverse events, blood and urine composition. the principal criterion of evaluation will be the variation in the extracellular compartment.

Eligibility criteria:
inclusion criteria: * \> or = to 18 years old * in whom an oral alkalinization is indicated exclusion criteria: * if the patient mentions its opposition to his/her enrollment

Keywords: bicarbonate
a methodological open label cross-over controlled study to assess the effect of drugs on ventricular repolarization and qt interval at fixed heart rate under autonomic blockade

Conditions: Patients With Pace Makers But no Evidence of Ischemic Heart Disease

Summary: to assess the effects of gtn on qt and qtc in subjects with and without atrial pacing. this will be done with and without autonomic blockade at two different pacing rates. moxifloxacin effect on qt and qtc will also be assessed in atrially paced patients at two different pacing rates with and without autonomic blockade


Eligibility criteria:
inclusion criteria: * patients with pace-makers but otherwise normal ventricular function exclusion criteria: * nitrates, beta blockers
performance of masimo invsensor00057 in detecting atrial fibrillation (afib)

Conditions: Atrial Fibrillation

Summary: this study is designed to validate the performance of masimo invsensor00057 in detecting atrial fibrillation. the noninvasive ecg measurements will be compared to results obtained from an fda-cleared ecg monitor.


Eligibility criteria:
inclusion criteria: * subject is 18 years of age or older. * subject is confirmed to have active atrial fibrillation at the time of enrollment. exclusion criteria: * subject is confirmed to have concurrent active arrhythmias (e.g., pvcs, bradycardia, etc.) at the time of enrollment. * subject is allergic to adhesives or ecg gel. * subject whose skin is not intact in or at the vicinity of the device placement site.
comparison of low and high ligation in the rectal cancer

Conditions: Rectal Cancer

Summary: the purpose of this study is to evaluate the defecatory function when nerve fibers around the inferior mesenteric artery(ima) and left colic artery(lca) are preserved(so called low ligation ) or not(high ligation) in the rectosigmoid and rectal cancer surgery.

fecal incontinence after anterior resection are often observed. whether or not postoperative bowel function is influenced by the preservation of nerve fibers around the root of ima and lca (low ligation) is still unknown. so in this randomized controlled trial, we evaluate the efficacy of low ligation in terms of the bowel function.

Eligibility criteria:
inclusion criteria: * on the basis of whether anterior resection was anticipated at wmuh for rectosigmoid and rectal cancer, and appropriate informed consent was obtained. exclusion criteria: * patients who could not respond to medical interview for own bowel function * patients without an informed consent

Keywords: low or high ligation
the expression and significance of mirna

Conditions: Pulmonary Arterial Hypertension

Summary: it is not always known what causes pah or what the best treatment is. the doctors doing this study would like to understand more about why some people develop pah and other do not. they also would like to learn more about which treatments might help pah and which people might respond better to treatments. doctors think that testing certain substances found in blood cells might help answer these questions. these substances are normally released by our bodies to protect us from infection and to tell the difference between normal and foreign substances in our body. finally, a new test will study very small molecules called microrna that control how our genes are expressed. this study is being done to see if blood samples can be tested to determine who might develop pah, how well drugs will work to treat pah and to learn more about the development of pah.

you will be asked to donate blood when you have your right heart catheterization and also at the 3-4 month follow-up visit. the amount of blood collected during your heart catheterization is about 20cc (about 4 teaspoons). this blood is discarded as part of the clinical catheterization procedure, but we are asking that we use it for this research study. then, at the follow-up right heart catheterization, you will be asked to donate 20 cc (which is about 4 teaspoons) of blood. if the second right heart is not required for clinical purposes then you will be asked to give a blood sample during your 3-4 month follow up clinic visit. if you require an additional right heart catheterization, within one year, we will ask that you donate additional samples at the subsequent rhc. other data collected as part of your clinical care, such as medical history, chest x-ray (picture of your lungs), echocardiogram (picture of your heart), ventilation perfusion scan (determines how much blood goes to your lungs), chest ct (thin pictures of my lungs as slices), pulmonary function tests (breathing tests), and lab blood tests, will be used as part of this research.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * not pregnant * undergoing right heart catheterization for pah diagnosis exclusion criteria: * pregnant

Keywords: mirna pulmonary arterial hypertension
indocyanine green fluorescence imaging, sentinel lymph node mapping in patients with vulvar cancer

Conditions: Vulvar Cancer

Summary: the potential of the administration of indocyanine green (icg) allows the execution of sln biopsy, avoiding the multiple administrations of radiocolloid in the pre-operative phase, painful for the patient, elimination, and exposure to radioactivity. therefore, while requiring standardization of the methodology and a large-scale application, this procedure could open a new surgical management perspective in patients with early-stage vulvar cancer.

according to the european society of gynaecological oncology (esgo) guidelines, the investigators decided to treat patients with vulvar squamous cell carcinoma (vscc), figo stage ib with radical vulvectomy, sentinel lymph node search, and removal with indocyanine green (icg) subsequent bilateral inguinofemoral lymphadenectomy. intraoperative imaging system the spy portable handheld imager (spy-phi) © stryker was used as the intraoperative imaging device. this device uses spy fluorescence imaging technology to visually assess blood circulation in blood vessels and associated tissue perfusion during surgery. the design of spy-phi makes the device versatile, enabling the operator to frame the operating field and use the acquired images in real-time, integrating fluorescence signal data with white light images in real-time. the spy portable handheld imaging system camera, with integrated optics and cables for real-time fluorescence imaging in visible light and near-infrared, is ideal for open surgery. intraoperative detection of the sentinel lymph node the fluorescent agent was administered to patients placed in the lithotomy position under general anesthesia. indocyanine green (icg) prepared with a 25 mg vial of green indocyanine green (icg) (pulsion medical systems ag, munich, germany) diluted in 50 ml of water for injections (b. braun medical) was used, resulting in a concentration of 0.5 mg/ml. injection of 1 ml per quadrant was administered in the three quadrants around the vulvar lesion. after the injection, the infrared camera, equipped with a movable arm, was placed in front of the patient to detect transcutaneous fluorescence during surgery. subsequently, the sln was localized based on the fluorescence intensity. the intraoperative fluorescence detection camera system was used to open, identify, and remove the sln and the vulvectomy of the groin. after the excision, the capture of the residual lymphatic pathway could be seen bilaterally through the infrared camera. additionally, all slns were subject to ex vivo imaging due to the presence of fluorescence. the excised slns were sent to pathological anatomy and processed according to the standard sln protocol.

Eligibility criteria:
inclusion criteria: * patients diagnosed with vulvar squamous cell carcinoma figo ib stage exclusion criteria: -

Keywords: vulvar cancer indocyanine green sentinel node surgery single center
promotion of breastfeeding intervention trial

Conditions: Effect of Breastfeeding on Maternal and Child Health Outcomes

Summary: the overall goal of the probit study is to investigate the influence of a randomized breastfeeding promotion intervention designed to increase the duration and exclusivity of breastfeeding ("the breastfeeding promotion intervention") on the development of maternal and child health outcomes. the hypothesis is that randomization to the intervention will be associated with lower child adiposity, lower risk of asthma and atopy, improved lung function, and improved cognitive outcomes.


Eligibility criteria:
inclusion criteria: * birth at one of 34 maternity hospitals in republic of belarus * breastfeeding initiated at birth, with no contraindications to breastfeeding * apgar score \>=5 at 5 minutes * full term gestation * birth weight \> 2500g

Keywords: breastfeeding child health obesity blood pressure asthma cognitive development behavior eczema lung function spirometry
respiratory syncytial virus infection in exacerbations of chronic obstructive pulmonary diasease: the recode study

Conditions: Respiratory Synctial Virus; COPD; Chronic Obstructive Pulmonary Disease (COPD); Exacerbation of COPD

Summary: the goal of this observational study is to determine the prevalence of respiratory syncytial virus (rsv) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (copd) who experience exacerbations during the rsv season (october-april). the main question it aims to answer is: * what is the prevalence of rsv infection in patients with copd during exacerbations in the rsv season? * does rsv infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and/or death in patients with copd exacerbations? researchers will compare patients with rsv infection to those without rsv infection to see if rsv infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death. participants will: * be adults diagnosed with copd who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms. * receive treatment as per standard clinical care for copd exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and/or oral corticosteroids if prescribed during hospitalization. * undergo diagnostic testing for rsv infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation. * have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period. * provide relevant demographic and clinical data, including medical history, copd severity, comorbidities, and previous exacerbation events.


Eligibility criteria:
inclusion criteria: * female or male * ≥50 years of age * seeking urgent medical attention because of ecopd, as defined by the rome consensus definition: "in a patient with copd, an exacerbation is an event characterized by dyspnea and/or cough and sputum that worsen over \<14 d, which may be accompanied by tachypnoea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways" exclusion criteria: * previous rsv vaccination (other vaccines will be allowed and recorded) * active cancer (or any other disease) that may alter the immune status of the patient * neurologic disorders that incapacitate the participation of the patient * no signing of the informed consent
the antiviral therapy in pregnant women to reduce mother-to-infant transmission of hepatitis b virus-drug test

Conditions: Hepatitis B Virus Infection, Pregnancy

Summary: since the implementation of universal vaccination in 1984, the chronic hbv carier rate in our general population reduced from 15-20%, down to \ 10\^8 copies/ml) will be recruited in the study; including 80-100 subjects treated with tenofovir 300 mg daily starting from 30-32 weeks of gestation (3rd trimester) and continued to 1 month after delivery; and 80-100 pregnant women are enrolled as controls with no drug given to the mother. the newborn babies are given with hbig within 24 hours after delivery, and hbv vaccines at 0, 1 and 6 months. maternal complete blood count (cbc) data tested in the first prenatal examination will be recorded. plasma ast、alt levels and hbv dna are tested before tenofovir treatment, 1 month after treatment, at the time of delivery, and at 1, 2, 4 and 6 months after delivery. hbsag、hbeag、anti-hbs and ast、alt are tested in the children at day 1, 6 moths and 1 year after birth. the primary outcome is reduction of the hbsag carrier rate of the children at 6 months of age. the secondary outcome is hbsag carrier rate of the children at 12 months of age, the change of liver function, hbeag, and viral load in pregnant mother after treatment. a follow-up study for investigating safety of mothers and children that has been exposed to maternal tenofovir disoproxil fumarate (tdf) during pregnancy in reducing mother-to-infant hepatitis b virus (hbv) transmissions is conducted. the follow-up study included mother-children pairs 2-4 years after delivery of the children.


Eligibility criteria:
inclusion criteria: - pregnant women in 30 to 32 weeks of gestation, with positive hbsag and hbeag,serum viral load above 8log10 copies per ml exclusion criteria: * major systemic disease * pregnant woman with infection of human immunodeficiency virus or hepatitis c virus * pregnant woman is receiving any drug with antiviral activity or any form of drug therapy for hepatitis b virus * pregnant woman whose ultrasonographic examination reveals congenital anomaly of the fetus * pregnant woman whose amniocentesis reveals any genetic abnormality

Keywords: hepatitis b virus,mother-infant transmission, nucleoside analog,pregnant women
effects of power-velocity muscle characteristics during ageing

Conditions: Sarcopenia

Summary: the purpose of this project is to investigate the age-related differences in force-velocity muscle characteristics during isolated knee extensions variable in speed and load, during cyclic movements on a usual and recumbent bike variable in speed and velocity development and a functional test battery with healthy participants aged between 20-80 years.


Eligibility criteria:
inclusion criteria: * healthy volunteers age 20 to 80 years exclusion criteria: * knee or hip prothesis * systematic training * cardiovascular disease * acute lower back pain * acute knee pain * dementia
pilot study to assess the pharmacokinetics of intravenous nabi 5% hepatitis b immune globulin (boca hbvig) used in combination with lamivudine for patients with hepatitis b virus (hbv) associated liver disease undergoing liver transplantation

Conditions: Hepatitis B Virus Associated Liver Disease

Summary: the purpose of this study is to find the best monthly dose schedule for the new hepatitis immune globulin (boca hbvig, a study drug) when used in combination with an antiviral agent lamivudine after liver transplantation. boca hbvig will be given along with lamivudine to prevent hepatitis b reinfection following liver transplantation in patients with end stage liver failure due to hepatitis b infection.


Eligibility criteria:
inclusion criteria: * be 18 years old or greater, either male or female, of any ethnic background. * be positive for hbsag. patients may be either positive or negative for anti-hdv, hbeag, and hbv dna (non-pcr assay). * be diagnosed with hbv-induced liver disease including either: * hbsag positive cirrhosis, or * hbsag positive and presence of hepatocellular carcinoma (hcc) with no evidence of vascular invasion or extrahepatic spread, and either: * a single tumor no larger than 5 cm in diameter, or * no more than three tumors, the largest of which is no greater than 3 cm in diameter. * have received at least one dose of lamivudine 100 mgs po qd prior to transplantation. * fulfill unos minimal listing criteria. * have received approval for liver transplantation at the respective participating center and are listed as status 2 or 3 and felt to be within three months of liver transplantation. * if requiring retransplantation for primary graft nonfunction or hepatic artery thrombosis, retransplantation must take place within the first four weeks of the initial transplant with no evidence of recurrent hepatitis b. * be able and willing to give written informed consent. in patients with grade 3 or 4 hepatic encephalopathy, a legal guardian must be available to provide consent. in the case of a minor, a parent or guardian must provide consent. * if a woman of childbearing potential, have a negative serum beta hcg pregnancy test within 14 days prior to starting lamivudine therapy and within 14 days prior to transplant and agree to practice contraception during the study (a total of 36 weeks). exclusion criteria: * eligible patients must not: * require retransplantation for recurrent hepatitis b. * have chronic hepatitis b liver disease with a history of breakthrough infection on lamivudine * have other causes of liver disease including chronic hepatitis c. * have hcc and do not meet inclusion criterion #3, or who require systemic chemotherapy. * be seropositive for hiv infection. * be using experimental devices or receiving experimental drugs. * be participating in any other clinical treatment trial with an investigational drug within 30 days prior to liver transplantation or plan to receive another investigational drug during this study.

Keywords: liver transplantation liver disease hepatitis b hepatitis b infection hepatitis b associated liver disease hbv
n-acetyl cysteine in post-reperfusion pulmonary injury in chronic thromboembolic pulmonary hypertension.

Conditions: Chronic Thromboembolic Pulmonary Hypertension

Summary: this study will evaluate the use of n-acetyl cysteine in post-reperfusion pulmonary injury in patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary balloon angioplasty and pulmonary endarterectomy. half of the patients will receive n-acetyl cysteine and the other placebo.

for chronic pulmonary embolism thrombus hypertension, the potentially curative treatment is endarterectomy, however in 12 to 60% it does not present surgical susceptibility, so pulmonary balloon angioplasty is the secondary option. in these procedures the complication that occurs most frequently is pulmonary oedema after reperfusion is a frequent complication (17.8-65%), appears between 24-72 hours after the intervention and the diagnosis is made in the presence of infiltrate interstitial in chest radiography or computed tomography of the chest. initially it was believed that it was difficult due to the increase in perfusion of secondary flow in the territory due to pulmonary vascular dilation, it is now believed that microtraumatism is involved by the guides and balloon used, vascular dysfunction and cytokines and innate immunity and adaptive, complement activation, coagulation cascade activation, apoptosis pathway activation, endothelial dysfunction caused by reperfusion contribute to cell dysfunction. the use of n-acetyl cysteine for its antioxidant properties, inflammatory response attenuator, reduction of reactive oxygen species (ros) and that in addition to having already had to reduce the condition of decrease in post-reperfusion ischemia15,16 in other situations is a viable option in the treatment of acute post-reperfusion edema in patients sometimes a pulmonary endarterectomy and balloon pulmonary angioplasty.

Eligibility criteria:
inclusion criteria: - patients who are diagnosed with group 4 pulmonary hypertension and are susceptible to pulmonary endarterectomy or balloon angioplasty in patients over 18 years. exclusion criteria: * patients who do not accept admission to the trial. * presence of arterial hypotension or sepsis.
magnetic resonance imaging study of cognitive-behavior therapy for major depressive disorder

Conditions: Major Depressive Disorder

Summary: study hypothesis: psychotherapy and ssri treatment effect in different brain way: psychotherapy in "up to down" way and ssri in "down to up" way. the investigators will explore this hypothesis in major depressive disorder outpatients with magnetic resonance imaging analysis in this study. patients in different groups will be treated by psychotherapy or ssri treatment. they will all be checked with magnetic resonance imaging pro and after 12 weeks of treatment.

patients meeting the inclusion criteria undergo an examination that included a diagnostic interview, vision test, and psychophysiological measures. participants then undergo the baseline fmri scan within 48 hours, after that, they will receive psychotherapy or ssri treatment.and returned the scan once they completed the therapy.

Eligibility criteria:
inclusion criteria: * meet scid -ⅰ/p major depressive disorder diagnosis; * right handedness; * good visual acuity. exclusion criteria: * neurological disease ; * serious physical illness (e.g. heart, lung, liver, kidney or blood system disease); * with other mental disorder; * psychotic symptoms * personality disorders; * pregnancy; * suicidal risk; * treatment by antidepressants or other psychotropic medications within 6 months prior to the start of the trial; * with contraindication for mri

Keywords: cognitive-behavior therapy magnetic resonance imaging major depressive disorder